Mitomycin C in Advanced Gallbladder Carcinoma

Abstract

Seven patients with advanced gallbladder carcinoma were given intraarterial infusions of 10 to 15 mg mitomycin C with 10 to 24 days' interval, 3 received intravenous infusion (10 mg/m2) with median 3 weeks' interval. Stationary disease was obtained in 4 patients, progressive disease in 4, and treatment failures in 2. The median survival after mitomycin C treatment was 4 months (range 1-23 +). Irreversible thrombocytopenia occurred in 2 patients and a severe gastrointestinal bleeding episode in one.